NCT06304961

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

Name: Clinical Trial NCT06304961
Creator: AstraZeneca
Keywords: Healthy Participants, Tozorakimab, Phase 1, biological, clinical trial, Germany

A Randomised, Single-dose, Parallel Group Study in Healthy Volunteers to Assess the Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration

AstraZeneca·Phase 1·ClinicalTrials.gov·biologicalRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Healthy Participants
Drug/Device/Intervention: Tozorakimab
Study type: Interventional
Intervention type: biological

Sponsor & location

Primary sponsor: AstraZeneca
Location: Berlin, Germany

Timeline & enrollment

Phase: Phase 1
Start date: Apr 08, 2024
End date: Sep 05, 2024
Enrollment: 46 participants

Primary outcome

Area under the concentration-time curve from time 0 to infinity (AUCinf),Area under the concentration-curve from time 0 to the last quantifiable concentration (AUClast),Maximum observed drug concentration (Cmax)

Summary

The study will assess the relative bioavailability between two dosage forms of tozorakimab (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles of both dosage forms.

ICD-10 classifications

Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06304961
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06304961 through Pure Global AI's free database. This Phase 1 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 46 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.